BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23178746)

  • 1. Treg cells in different forms of uterine cancer.
    Hou F; Ma D; Cui B
    Clin Chim Acta; 2013 Jan; 415():337-40. PubMed ID: 23178746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.
    Nakamura T; Shima T; Saeki A; Hidaka T; Nakashima A; Takikawa O; Saito S
    Cancer Sci; 2007 Jun; 98(6):874-81. PubMed ID: 17433037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and maintenance of regulatory T cells.
    Ohkura N; Kitagawa Y; Sakaguchi S
    Immunity; 2013 Mar; 38(3):414-23. PubMed ID: 23521883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
    Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine 2,3-dioxygenase.
    Li W; Li B; Fan W; Geng L; Li X; Li L; Huang Z; Li S
    J Reprod Immunol; 2009 Jun; 80(1-2):1-11. PubMed ID: 19362742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
    Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
    Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I diabetes.
    Kornete M; Piccirillo CA
    Autoimmun Rev; 2011 Dec; 11(2):104-11. PubMed ID: 21875694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
    Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
    Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting regulatory T cells in tumors.
    Liu C; Workman CJ; Vignali DA
    FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice.
    Suffner J; Hochweller K; Kühnle MC; Li X; Kroczek RA; Garbi N; Hämmerling GJ
    J Immunol; 2010 Feb; 184(4):1810-20. PubMed ID: 20083650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymic and peripheral differentiation of regulatory T cells.
    Lee HM; Bautista JL; Hsieh CS
    Adv Immunol; 2011; 112():25-71. PubMed ID: 22118406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
    Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
    Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of regulatory T-cell lineage.
    Hori S
    Adv Immunol; 2011; 112():1-24. PubMed ID: 22118405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional control of regulatory T cells and cancer immunotherapy.
    Wang RF
    Semin Cancer Biol; 2006 Apr; 16(2):106-14. PubMed ID: 16423537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.
    Wei S; Kryczek I; Edwards RP; Zou L; Szeliga W; Banerjee M; Cost M; Cheng P; Chang A; Redman B; Herberman RB; Zou W
    Cancer Res; 2007 Aug; 67(15):7487-94. PubMed ID: 17671219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis.
    Lewkowicz N; Lewkowicz P; Dzitko K; Kur B; Tarkowski M; Kurnatowska A; Tchórzewski H
    J Oral Pathol Med; 2008 Sep; 37(8):454-61. PubMed ID: 18318707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXP3+ regulatory T cells: Current controversies and future perspectives.
    Banham AH; Powrie FM; Suri-Payer E
    Eur J Immunol; 2006 Nov; 36(11):2832-6. PubMed ID: 17051620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional regulation of Foxp3 in regulatory T cells.
    Haiqi H; Yong Z; Yi L
    Immunobiology; 2011 Jun; 216(6):678-85. PubMed ID: 21122941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.